Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.
about
Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patientsTreatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosisTreatment for chronic Staphylococcus aureus pulmonary infection in people with cystic fibrosisTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisStenotrophomonas maltophilia: an emerging global opportunistic pathogenThe Role of Bacterial Secretion Systems in the Virulence of Gram-Negative Airway Pathogens Associated with Cystic FibrosisRespiratory infection rates differ between geographically distant paediatric cystic fibrosis cohortsActivation of the pyrin inflammasome by intracellular Burkholderia cenocepaciaLongitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis methodThe effects of inhaled aztreonam on the cystic fibrosis lung microbiome.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyGenomic analysis and relatedness of P2-like phages of the Burkholderia cepacia complex.Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic FibrosisThe changing microbial epidemiology in cystic fibrosis.Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient.Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis.The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbationsClinical significance of microbial infection and adaptation in cystic fibrosis.Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, OhioDevelopment and antimicrobial susceptibility studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus fumigatus and Pseudomonas aeruginosa.Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infectionPseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical responseLung microbiota across age and disease stage in cystic fibrosis.Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patientsThe cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy.Outcomes and Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Differs by Staphylococcal Cassette Chromosome mec (SCCmec) Type in Children With Cystic Fibrosis.The Dynamics of Disease Progression in Cystic Fibrosis.Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Proteome Analyses of Staphylococcus aureus Biofilm at Elevated Levels of NaCl.Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosisTwenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.Inhaled antibiotics for gram-negative respiratory infections.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Current dilemmas in antimicrobial therapy in cystic fibrosis.Staphylococcus aureus in early cystic fibrosis lung disease.
P2860
Q21562196-9688CC27-6410-4D2D-B6D5-E372029F1674Q24186014-70DE537D-5CF3-4BF8-88FE-FC44E59149D6Q24187701-17202BAF-B86F-4330-8055-A20D45A4C96BQ26829604-60FA33B2-A49F-40F5-AF0F-589E96E1873FQ26995336-9FAA3C2A-B6DD-4BC5-A72D-F943D81780E0Q28068051-66FD7722-1E75-4C40-8B52-E06475052649Q28589362-3446D6FA-CE7B-48D1-8F41-D9523EB2F679Q30527774-D25B78FE-CEAE-4F53-ADB1-5FD09259F236Q33526875-986672FF-8A45-4C50-95AB-91DCCF0E5601Q33644835-B714BD22-2931-405C-AB55-3CF288B129DEQ33697276-CFF13FD7-5C2E-4372-B0C1-12D772193137Q33727287-193BBE56-AE5A-43F0-B9F9-F560CAB7CC88Q33783497-88C746EB-6DE8-4075-B48D-1A30E320EBBAQ33825634-8E819790-92C7-4E55-87F6-5BC0A30D7F34Q33929671-794A3C5B-D6B8-4521-8B45-AF63214D1C8DQ34017905-23ADBB60-4040-421F-9F61-396EE18018A6Q34150150-6E064DD5-74E8-4473-A323-9C052679E1D8Q34437958-000F8629-63B9-4954-B647-412ED03656DDQ34491552-CCBC8E45-3F02-4345-8A33-ADF4A3E7474BQ34737606-89A3B00E-06F9-4F9C-AB3C-6B679652273CQ35109394-B33675F5-3C6E-4301-9FE5-5BA9B46153C8Q35113179-4E94851B-6E77-40CA-B232-8E8439BC95CFQ35127240-4188C32A-A1E0-411B-B0AC-A4C68F3230BCQ35358667-09F8999A-B6E2-4502-9E34-ABE9A69D62C4Q35605802-49B930F3-DEE6-4B54-BE3D-A6EBF33FC7D9Q35669548-D2549A01-7864-4579-B709-6E77711E9D2BQ35861377-33DABAAD-2DF9-4952-B937-3B325145CD71Q36009637-C12CCC8E-1032-4716-AD5A-3A5A6B015F8FQ36036190-9F65A33C-BFA5-4BBD-ABF5-154C9C8A90BBQ36658777-00066609-F6DC-4991-AD99-A08FE03C3F6FQ36672783-6DF83F01-4CE8-413F-8351-ED5BF50597B8Q37026521-2285A0CE-E1CA-43F0-83A7-15DDD1F33A7EQ37463364-B8C1A6B2-0C21-4862-BB08-6148B3340935Q37713415-56924E3E-F993-4657-BF8E-E6A85CA0DA4FQ37775620-76212FCA-C0D5-431F-927C-F13AC86AD7A5Q37866819-8FA7A929-8147-4FFE-A3DB-1235D711EDFBQ37937558-1ADFC004-845B-46D4-972E-53DBCE77DA74Q37940005-7F74641F-BD87-4986-B5A9-634363464BCBQ38042719-857B5E2C-3F0D-4801-AB5F-5D48674F23B4Q38130897-F762354F-1B52-42C8-A488-38D5E008BA63
P2860
Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@en
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@nl
type
label
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@en
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@nl
prefLabel
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@en
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@nl
P2093
P921
P356
P1433
P1476
Respiratory microbiology of pa ...... e United States, 1995 to 2005.
@en
P2093
Ase Sewall
Bruce Marshall
Hebe Quinton
Lisa Saiman
Lynne Quittell
Samiya Razvi
P304
P356
10.1378/CHEST.09-0132
P407
P577
2009-06-08T00:00:00Z